An Open Label Continuation Study of the Effects of TRx0014 [methylthioninium chloride] 30 mg TID [three times a day] and 60 mg TID in Patients With Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Methylthioninium chloride-TauRx (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors TauRx Therapeutics
- 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Jun 2008 New trial record.